Literature DB >> 15024487

[Severe microangiopathic hemolytic anemia as first manifestation of a CUP syndrome. Rapid hematologic remission under polychemotherapy].

Ahmed Abdel Samie1, Bettina Sandritter, Lorenz Theilmann.   

Abstract

BACKGROUND: Microangiopathic hemolytic anemia (MAHA) represents a rare manifestation of malignant tumors. This complication, which is mainly lethal within a few weeks, is most commonly observed in association with mucin-producing adenocarcinomas, especially gastric cancer. The pathogenesis of tumor-associated mechanical hemolysis remains unclear. A standard therapy of this hematologic disturbance is not established. CASE REPORT: The authors report on a 51-year-old patient, who presented himself in their clinic with severe anemia, thrombopenia and deterioration of his general condition. Extensive investigations revealed signet-ring carcinoma metastases in the whole vertebral column, pelvis and bone marrow. The primary tumor could neither be located endoscopically nor in imaging examinations. Under palliative chemotherapy with cisplatin, epirubicin and 5-fluorouracil continuous infusion, a rapid objective and subjective improvement could be achieved, which was reflected in normalization of the blood picture and regression of the osteoplastic bone metastases indicating partial remission. 9 months later, the patient died because of a new progression of his disease.
CONCLUSION: MAHA can be the first manifestation of malignant tumors. Upon the diagnosis of a MAHA, rapid diagnostics should be done to detect a possible underlying tumor, as effective antineoplastic therapy can induce both tumor and hematologic remission.

Entities:  

Mesh:

Year:  2004        PMID: 15024487     DOI: 10.1007/s00063-004-1023-8

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  6 in total

1.  Breast Cancer-Associated Thrombotic Microangiopathy.

Authors:  Anne C Regierer; Dagmar Kuehnhardt; Carsten-Oliver Schulz; Bernd Flath; Christian F Jehn; Christian W Scholz; Kurt Possinger; Jan Eucker
Journal:  Breast Care (Basel)       Date:  2011-12-15       Impact factor: 2.860

Review 2.  Microangiopathic hemolytic anemia as the first manifestation of metastatic signet ring cell carcinoma of unknown origin: a case report and review of literature.

Authors:  Sang-Yong Shin; Hyosoon Park; Seoung Wan Chae; Hee-Yeon Woo
Journal:  Korean J Lab Med       Date:  2011-06-28

3.  A rare case of concurrent signet-ring carcinoma of breast and microangiopathic hemolytic anemia.

Authors:  Kelly Lara; Esther Bae; Hanna Park; Farabi Hussain
Journal:  J Surg Case Rep       Date:  2016-09-01

4.  A Metastatic Signet Ring Cell Carcinoma Presented as Acquired Thrombotic Thrombocytopenic Purpura: A Case Report.

Authors:  Noha Eisa; Khalid Nasef; Ziad Emarah; Marwa Mohamed Abdel Fattah; Sameh Shamaa
Journal:  J Hematol (Brossard)       Date:  2018-05-10

5.  Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study.

Authors:  Marion Alhenc-Gelas; Luc Cabel; Frederique Berger; Suzette Delaloge; Jean-Sebastien Frenel; Christelle Levy; Nelly Firmin; Sylvain Ladoire; Isabelle Desmoulins; Pierre-Etienne Heudel; Florence Dalenc; Delphine Loirat; Coraline Dubot; Perrine Vuagnat; Elise Deluche; Meriem Mokdad-Adi; Anne Patsouris; Josselin Annic; Lounes Djerroudi; Marion Lavigne; Jean-Yves Pierga; Paul Coppo; Francois-Clement Bidard
Journal:  Breast Cancer Res       Date:  2021-01-19       Impact factor: 6.466

6.  Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study.

Authors:  Robert Lam; Nicholas Tarangelo; Rong Wang; Masayasu Horibe; Alyssa A Grimshaw; Dhanpat Jain; Samir Haffar; Fateh Bazerbachi; Pamela L Kunz; Darrick K Li
Journal:  Oncologist       Date:  2022-09-02       Impact factor: 5.837

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.